Jeffrey A Cohen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2034013/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairment. Multiple Sclerosis Journal, 2022, 28, 817-830.	3.0	2
2	Symptomatic and restorative therapies in neuromyelitis optica spectrum disorders. Journal of Neurology, 2022, 269, 1786-1801.	3.6	8
3	Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions. Multiple Sclerosis Journal, 2022, 28, 1131-1137.	3.0	13
4	Confirming a Historical Diagnosis of Multiple Sclerosis. Neurology: Clinical Practice, 2022, 12, 263-269.	1.6	4
5	Perspectives and experiences with COVID-19 vaccines in people with MS. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2022, 8, 205521732210852.	1.0	7
6	Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II. Multiple Sclerosis Journal, 2022, 28, 1562-1575.	3.0	25
7	Treatment Challenges in Multiple Sclerosis – A Continued Role for Glatiramer Acetate?. Frontiers in Neurology, 2022, 13, 844873.	2.4	4
8	Nursing, Diabetes, Hemodialysis and COVID-19. Journal of Religion and Health, 2022, 61, 1767-1771.	1.7	0
9	Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial. Multiple Sclerosis Journal, 2022, 28, 1944-1962.	3.0	16
10	Early versus delayed treatment with glatiramer acetate: Analysis of up to 27 years of continuous follow-up in a US open-label extension study. Multiple Sclerosis Journal, 2022, 28, 1729-1743.	3.0	1
11	Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS. Multiple Sclerosis and Related Disorders, 2021, 48, 102673.	2.0	20
12	Evolution of the Diagnostic Criteria in Multiple Sclerosis. , 2021, , 75-87.		0
13	Early age of onset predicts severity of visual impairment in patients with neuromyelitis optica spectrum disorder. Multiple Sclerosis Journal, 2021, 27, 1749-1759.	3.0	4
14	Consensus Curriculum for Fellowship Training in Multiple Sclerosis and Neuroimmunology. Neurology: Clinical Practice, 2021, 11, 352-357.	1.6	1
15	MRI findings in blinded trials should be available to treating physicians – No. Multiple Sclerosis Journal, 2021, 27, 814-815.	3.0	1
16	Disability improvement as a clinically relevant outcome in clinical trials of relapsing forms of multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 2219-2231.	3.0	7
17	Multiple Sclerosis Wellness Shared Medical Appointment Model: A Pilot Study. International Journal of MS Care, 2021, 23, 229-233.	1.0	1
18	Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program. Multiple Sclerosis and Related Disorders, 2021, 51, 102844.	2.0	19

#	Article	IF	CITATIONS
19	Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials. European Journal of Neurology, 2021, 28, 3722-3730.	3.3	12
20	Clinical Perspectives on the Molecular and Pharmacological Attributes of Anti-CD20 Therapies for Multiple Sclerosis. CNS Drugs, 2021, 35, 985-997.	5.9	26
21	Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions. Lancet, The, 2021, 398, 1184-1194.	13.7	113
22	Clinical features and outcomes of COVID-19 despite SARS-CoV-2 vaccination in people with multiple sclerosis Journal - Experimental, Translational and Clinical, 2021, 7, 205521732110571.	1.0	16
23	Women's Health in Multiple Sclerosis: A Scoping Review. Frontiers in Neurology, 2021, 12, 812147.	2.4	8
24	Perspectives of individuals with multiple sclerosis on discontinuation of disease-modifying therapies. Multiple Sclerosis Journal, 2020, 26, 1581-1589.	3.0	13
25	Palatal myoclonus, abnormal eye movements, and olivary hypertrophy in GAD65-related disorder. Neurology, 2020, 94, 273-275.	1.1	6
26	Technology-enabled comprehensive characterization of multiple sclerosis in clinical practice. Multiple Sclerosis and Related Disorders, 2020, 38, 101525.	2.0	11
27	Leveraging real-world data to investigate multiple sclerosis disease behavior, prognosis, and treatment. Multiple Sclerosis Journal, 2020, 26, 23-37.	3.0	55
28	Safety results of administering ocrelizumab per a shorter infusion protocol in patients with primary progressive and relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 46, 102454.	2.0	15
29	COVID-19 in people with multiple sclerosis: A global data sharing initiative. Multiple Sclerosis Journal, 2020, 26, 1157-1162.	3.0	50
30	The Rise and Fall of High-Dose Biotin to Treat Progressive Multiple Sclerosis. Neurotherapeutics, 2020, 17, 968-970.	4.4	5
31	Multiple sclerosis management during the COVID-19 pandemic. Multiple Sclerosis Journal, 2020, 26, 1163-1171.	3.0	63
32	Ofatumumab versus Teriflunomide in Multiple Sclerosis. New England Journal of Medicine, 2020, 383, 546-557.	27.0	358
33	Long-term ocrelizumab in progressive multiple sclerosis. Lancet Neurology, The, 2020, 19, 966-968.	10.2	1
34	Response of the multiple sclerosis community to COVID-19. Multiple Sclerosis Journal, 2020, 26, 1134-1136.	3.0	5
35	Long-term prognostic value of longitudinal measurements of blood neurofilament levels. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	27
36	The 2013 clinical course descriptors for multiple sclerosis. Neurology, 2020, 94, 1088-1092.	1.1	73

#	Article	IF	CITATIONS
37	Keep the Worms in the Mud. JAMA Neurology, 2020, 77, 1066.	9.0	3
38	Technology-enabled assessments to enhance multiple sclerosis clinical care and research. Neurology: Clinical Practice, 2020, 10, 222-231.	1.6	12
39	Continuing Clinical Research During <scp>Shelterâ€inâ€Place</scp> . Annals of Neurology, 2020, 88, 658-660.	5.3	5
40	Advances in oral immunomodulating therapies in relapsing multiple sclerosis. Lancet Neurology, The, 2020, 19, 336-347.	10.2	90
41	Determining the effectiveness of early intensive versus escalation approaches for the treatment of relapsing-remitting multiple sclerosis: The DELIVER-MS study protocol. Contemporary Clinical Trials, 2020, 95, 106009.	1.8	31
42	Intrinsic and Extrinsic Mechanisms of Thalamic Pathology in Multiple Sclerosis. Annals of Neurology, 2020, 88, 81-92.	5.3	33
43	Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study. Multiple Sclerosis Journal, 2019, 25, 1255-1262.	3.0	37
44	Early initiation of fingolimod reduces the rate of severe relapses over the long term: Post hoc analysis from the FREEDOMS, FREEDOMS II, and TRANSFORMS studies. Multiple Sclerosis and Related Disorders, 2019, 36, 101335.	2.0	6
45	Comparative discontinuation, effectiveness, and switching practices of dimethyl fumarate and fingolimod at 36-month follow-up. Journal of the Neurological Sciences, 2019, 407, 116498.	0.6	14
46	Extended treatment with fingolimod for relapsing multiple sclerosis: the 14-year LONGTERMS study results. Therapeutic Advances in Neurological Disorders, 2019, 12, 175628641987832.	3.5	54
47	Evaluation of multiple sclerosis disability outcome measures using pooled clinical trial data. Neurology, 2019, 93, e1921-e1931.	1.1	58
48	Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurology, The, 2019, 18, 1009-1020.	10.2	191
49	Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurology, The, 2019, 18, 1021-1033.	10.2	184
50	Lymphocyte counts and infection rates. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6,	6.0	7
51	Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. Lancet Neurology, The, 2019, 18, 185-197.	10.2	110
52	Developing therapeutic strategies to promote myelin repair in multiple sclerosis. Expert Review of Neurotherapeutics, 2019, 19, 997-1013.	2.8	13
53	Exploratory MRI measures after intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019, 5, 205521731985603.	1.0	8
54	The emergence of follow-on disease-modifying therapies for multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 1560-1565.	3.0	7

#	Article	IF	CITATIONS
55	Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 845-854.	2.0	69
56	Serum neurofilament light chain concentration in a phase 1/2 trial of autologous mesenchymal stem cell transplantation. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019, 5, 205521731988719.	1.0	7
57	Pregnancy and multiple sclerosis: Risk of unplanned pregnancy and drug exposure in utero. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019, 5, 205521731989174.	1.0	7
58	Movement disorders in early MS and related diseases. Neurology: Clinical Practice, 2019, 9, 24-31.	1.6	22
59	The FLUENT study design: investigating immune cell subset and neurofilament changes in patients with relapsing multiple sclerosis treated with fingolimod. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019, 5, 205521731881924.	1.0	3
60	Symbol Digit Modalities Test: A valid clinical trial endpoint for measuring cognition in multiple sclerosis Journal, 2019, 25, 1781-1790.	3.0	129
61	Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study. Multiple Sclerosis Journal, 2019, 25, 1605-1617.	3.0	57
62	Safety and efficacy of ADS-5102 (amantadine) extended release capsules to improve walking in multiple sclerosis: A randomized, placebo-controlled, phase 2 trial. Multiple Sclerosis Journal, 2019, 25, 601-609.	3.0	8
63	Mesenchymal Stem Cell-derived Neural Progenitor Cells in Progressive Multiple Sclerosis: Great Expectations. EBioMedicine, 2018, 29, 5-6.	6.1	6
64	Feasibility of mesenchymal stem cell culture expansion for a phase I clinical trial in multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2018, 4, 205521731876528.	1.0	7
65	Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurology, The, 2018, 17, 162-173.	10.2	4,605
66	Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 501-511.	3.0	86
67	The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability. Multiple Sclerosis Journal, 2018, 24, 1469-1484.	3.0	41
68	Applying the 2017 McDonald diagnostic criteria for multiple sclerosis – Authors' reply. Lancet Neurology, The, 2018, 17, 499-500.	10.2	35
69	Integrating multiple sclerosis guidelines into practice. Lancet Neurology, The, 2018, 17, 658-660.	10.2	5
70	Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers. Neurology: Clinical Practice, 2018, 8, 292-301.	1.6	25
71	The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis Journal, 2017, 23, 94-105.	3.0	95
72	Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis Journal, 2017, 23, 704-710.	3.0	270

#	Article	IF	CITATIONS
73	Switching from branded to generic glatiramer acetate: 15-month GATE trial extension results. Multiple Sclerosis Journal, 2017, 23, 1909-1917.	3.0	23
74	CNS disease diminishes the therapeutic functionality of bone marrow mesenchymal stem cells. Experimental Neurology, 2017, 295, 222-232.	4.1	13
75	Effect of Template Reporting of Brain MRIs for Multiple Sclerosis on Report Thoroughness and Neurologist-Rated Quality: Results of a Prospective Quality Improvement Project. Journal of the American College of Radiology, 2017, 14, 371-379.e1.	1.8	49
76	Clemastine fumarate for promotion of optic nerve remyelination. Lancet, The, 2017, 390, 2421-2422.	13.7	11
77	Clinical outcome measures for progressive MS trials. Multiple Sclerosis Journal, 2017, 23, 1627-1635.	3.0	32
78	Alemtuzumab CARE-MS I 5-year follow-up. Neurology, 2017, 89, 1107-1116.	1.1	188
79	Alemtuzumab CARE-MS II 5-year follow-up. Neurology, 2017, 89, 1117-1126.	1.1	232
80	Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 24-month follow-up. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2017, 3, 205521731771548.	1.0	28
81	Sphingosine 1-Phosphate Receptor Modulators for the Treatment of Multiple Sclerosis. Neurotherapeutics, 2017, 14, 859-873.	4.4	105
82	Comorbidities in MS are associated with treatment intolerance and disability. Neurology, 2017, 89, 2218-2219.	1.1	1
83	Safety of monoclonal antibodies for the treatment of multiple sclerosis. Expert Opinion on Drug Safety, 2017, 16, 89-100.	2.4	27
84	Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function. Lancet, The, 2017, 389, 1357-1366.	13.7	235
85	Cell-based therapeutic strategies for multiple sclerosis. Brain, 2017, 140, 2776-2796.	7.6	139
86	Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program. Therapeutics and Clinical Risk Management, 2017, Volume 13, 1423-1437.	2.0	25
87	Should MRI be the primary endpoint of phase 3 trials in multiple sclerosis?. Expert Review of Clinical Immunology, 2016, 12, 489-491.	3.0	0
88	Fingolimod failure in progressive MS INFORMS future trials. Nature Reviews Neurology, 2016, 12, 253-254.	10.1	8
89	Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients. Neurology, 2016, 87, 1985-1992.	1.1	55
90	Lack of magnetic resonance imaging lesion activity as a treatment target in multiple sclerosis: An evaluation using electronically collected outcomes. Multiple Sclerosis and Related Disorders, 2016, 9, 129-134.	2.0	4

#	Article	IF	CITATIONS
91	Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up. Multiple Sclerosis and Related Disorders, 2016, 10, 44-52.	2.0	43
92	Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon \hat{l}^2 -1a in MS. Neurology, 2016, 87, 1464-1472.	1.1	28
93	Human Mesenchymal Stem Cells Impact Th17 and Th1 Responses Through a Prostaglandin E2 and Myeloid-Dependent Mechanism. Stem Cells Translational Medicine, 2016, 5, 1506-1514.	3.3	73
94	The challenge of comorbidity in clinical trials for multiple sclerosis. Neurology, 2016, 86, 1437-1445.	1.1	48
95	Recommendations for observational studies of comorbidity in multiple sclerosis. Neurology, 2016, 86, 1446-1453.	1.1	64
96	Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial. Lancet Neurology, The, 2016, 15, 373-381.	10.2	150
97	Long-term (up to 4.5â€years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 468-475.	1.9	137
98	Switching sides—fingolimod versus injectable MS therapies. Nature Reviews Neurology, 2015, 11, 316-317.	10.1	3
99	A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: Overview. Multiple Sclerosis Journal, 2015, 21, 263-281.	3.0	273
100	Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis. Neurology, 2015, 84, 784-793.	1.1	119
101	The incidence and prevalence of comorbid gastrointestinal, musculoskeletal, ocular, pulmonary, and renal disorders in multiple sclerosis: A systematic review. Multiple Sclerosis Journal, 2015, 21, 332-341.	3.0	39
102	Vision and vision-related outcome measures in multiple sclerosis. Brain, 2015, 138, 11-27.	7.6	168
103	Sphingosine 1-Phosphate Receptor Modulators in Multiple Sclerosis. CNS Drugs, 2015, 29, 565-575.	5.9	117
104	Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis. JAMA Neurology, 2015, 72, 1433.	9.0	67
105	A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 282-293.	3.0	131
106	Experience with fingolimod in clinical practice. International Journal of Neuroscience, 2015, 125, 678-685.	1.6	31
107	Improvement of internuclear ophthalmoparesis in multiple sclerosis with dalfampridine. Neurology, 2014, 83, 192-194.	1.1	14
108	Alemtuzumab for the treatment of relapsing–remitting multiple sclerosis. Immunotherapy, 2014, 6, 249-259.	2.0	20

#	Article	IF	CITATIONS
109	The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing–Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 1704-1713.	3.0	41
110	Fingolimod in relapsing multiple sclerosis: An integrated analysis of safety findings. Multiple Sclerosis and Related Disorders, 2014, 3, 494-504.	2.0	105
111	First-dose effects of fingolimod: Pooled safety data from three phase 3 studies. Multiple Sclerosis and Related Disorders, 2014, 3, 629-638.	2.0	68
112	Venous angioplasty for "CCSVl―in multiple sclerosis. Neurology, 2014, 83, 388-389.	1.1	8
113	Natalizumab and fingolimod: Insight into their relative efficacies in clinical practice. Multiple Sclerosis Journal, 2014, 20, 1280-1281.	3.0	1
114	Defining the clinical course of multiple sclerosis. Neurology, 2014, 83, 278-286.	1.1	2,344
115	Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis. Neurology, 2014, 82, 674-680.	1.1	135
116	Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. Journal of Neurology, 2013, 260, 2023-2032.	3.6	82
117	The benefits and risks of alemtuzumab in multiple sclerosis. Expert Review of Clinical Immunology, 2013, 9, 189-191.	3.0	4
118	Mesenchymal stem cell transplantation in multiple sclerosis. Journal of the Neurological Sciences, 2013, 333, 43-49.	0.6	110
119	Fingolimod Therapy for Multiple Sclerosis. Seminars in Neurology, 2013, 33, 037-044.	1.4	42
120	Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet, The, 2012, 380, 1819-1828.	13.7	1,041
121	Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet, The, 2012, 380, 1829-1839.	13.7	1,040
122	Early tolerability and safety of fingolimod in clinical practice. Journal of the Neurological Sciences, 2012, 323, 167-172.	0.6	44
123	Multiple Sclerosis: New Insights in Pathogenesis and Novel Therapeutics. Annual Review of Medicine, 2012, 63, 389-404.	12.2	64
124	Handbook of Multiple Sclerosis. , 2012, , .		9
125	Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects. Lancet Neurology, The, 2012, 11, 467-476.	10.2	211
126	Potential mechanisms of efficacy and adverse effects in the use of fingolimod (FTY720). Expert Review of Clinical Pharmacology, 2011, 4, 567-570.	3.1	14

#	Article	IF	CITATIONS
127	The use of MRI in multiple sclerosis clinical trials. , 2011, , 198-212.		0
128	Multiple sclerosis: advances in understanding pathogenesis and emergence of oral treatment options. Lancet Neurology, The, 2011, 10, 4-5.	10.2	10
129	Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurology, The, 2011, 10, 520-529.	10.2	204
130	Phase III dose omparison study of glatiramer acetate for multiple sclerosis. Annals of Neurology, 2011, 69, 75-82.	5.3	65
131	Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Annals of Neurology, 2011, 69, 292-302.	5.3	8,001
132	Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis. Annals of Neurology, 2011, 69, 759-777.	5.3	344
133	Fingolimod. Neurology: Clinical Practice, 2011, 1, 61-65.	1.6	6
134	Emerging Oral Therapies in Multiple Sclerosis. Current Neurology and Neuroscience Reports, 2010, 10, 381-388.	4.2	18
135	Combination therapy in multiple sclerosis. Lancet Neurology, The, 2010, 9, 299-308.	10.2	106
136	Reciprocal Th1 and Th17 regulation by mesenchymal stem cells: Implication for multiple sclerosis. Annals of Neurology, 2010, 68, 540-545.	5.3	69
137	Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis. New England Journal of Medicine, 2010, 362, 402-415.	27.0	1,983
138	Emerging Therapies for Relapsing Multiple Sclerosis. Archives of Neurology, 2009, 66, 821-8.	4.5	27
139	The future of multiple sclerosis treatment. Journal of the Neurological Sciences, 2009, 277, S55-S61.	0.6	7
140	Evaluation of the six-minute walk in multiple sclerosis subjects and healthy controls. Multiple Sclerosis Journal, 2008, 14, 383-390.	3.0	535
141	How effective is intravenous immunoglobulin for the treatment of relapsing–remitting multiple sclerosis?. Nature Clinical Practice Neurology, 2008, 4, 588-589.	2.5	7
142	Multiple sclerosis symptom management. Expert Review of Neurotherapeutics, 2007, 7, 1213-1222.	2.8	39
143	Appraisal of the multiple sclerosis functional composite. Expert Review of Neurotherapeutics, 2003, 3, 335-341.	2.8	1
144	Use of the Multiple Sclerosis Functional Composite as an Outcome Measure in a Phase 3 Clinical Trial. Archives of Neurology, 2001, 58, 961.	4.5	151

#	Article	IF	CITATIONS
145	The Potential for Vigabatrin-Induced Intramyelinic Edema in Humans. Epilepsia, 2000, 41, 148-157.	5.1	75
146	Multiple sclerosis, porphyria-like symptoms, and a history of iron deficiency anemia in a family of Scottish descent. , 1999, 86, 194-196.		15
147	Newer Versus Older Treatments for Relapsing-Remitting Multiple Sclerosis. Drug Safety, 1996, 14, 121-130.	3.2	5
148	Ligand Binding to the Cell-Surface Receptor for Reovirus Type 3 Alters Schwann Cell Growth and Function. Annals of the New York Academy of Sciences, 1990, 605, 412-415.	3.8	0
149	A point mutation in the neu oncogene mimics ligand induction of receptor aggregation. Nature, 1989, 339, 230-231.	27.8	432
150	Truncal ataxia presumably due to malignant spinal cord compression. Annals of Neurology, 1987, 21, 511-512.	5.3	0
151	Assessment of neuropsychological function in multiple sclerosis. , 0, , 65-78.		0
152	Measurement of CNS atrophy. , 0, , 128-149.		2
153	Treatment for patients with primary progressive multiple sclerosis. , 0, , 604-613.		0
154	Management of pediatric multiple sclerosis. , 0, , 632-644.		0
155	Management of medical comorbidities in patients with multiple sclerosis. , 0, , 714-723.		0
156	Fingolimod to treat multiple sclerosis. , 0, , 370-386.		0